hit counter

SSRIs + DOACs: No Excess Bleeding vs. Other Antidepressants

Stylized illustration of an SSRI capsule alongside a DOAC tablet against a vascular network background, representing the bleeding-interaction question in primary care.

SSRIs raise bleeding risk on their own. DOACs (direct oral anticoagulants — apixaban, rivaroxaban, dabigatran, edoxaban) raise it more. The intuitive worry is that combining them stacks the two effects. A new BJGP Open analysis from Chau and colleagues argues the stacking is smaller than most popular framings claim, and that the real safety question …

Read more